- Boehringer joins trial program to advance treatments for AMLwestfaironline.com
- Gilead’s Growth Tonic Is Elusive, May Have Side Effectswsj.com
- The Motley Fool: Biotech firm has the market for hepatitis C drugs in its grasp - Sun, 27 Dec 2015 PSTThe Spokesman-Review
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.